Update [12/18/2019] FDA is alerting patients and health care professionals to Glenmark Pharmaceutical Inc.'s voluntary recall of prescription ranitidine tablets (150 mg and 300 mg). The medicines are being recalled because they may contain unacceptable levels of N-nitrosodimethylamine (NDMA).